ACADIA Pharmaceuticals Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Catherine Owen Adams
- Full Time Employees
- 798
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 12830 El Camino Real San Diego CA United States 92130
- IPO Date
- May 27, 2004
- CIK
- 0001070494
- Website
- acadia.com
- Similar Companies
- Business
- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) is a biopharmaceutical company that discovers, develops, and commercializes innovative medicines targeting unmet medical needs in central nervous system disorders and rare diseases; its commercial portfolio features NUPLAZID (pimavanserin), the first and only FDA-approved treatment for hallucinations and delusions associated with Parkinson's disease psychosis, and DAYBUE (trofinetide), the first and only FDA-approved treatment for Rett syndrome in patients aged two years and older. The company advances a robust pipeline including mid- to late-stage candidates such as ACP-204 for Lewy body dementia psychosis and programs in Alzheimer's disease psychosis, alongside earlier-stage efforts addressing Prader-Willi syndrome negative symptoms, treatment-resistant depression (ACP-211), Huntington's disease and tardive dyskinesia (ACP-271), and essential tremor (ACP-711). ACADIA operates primarily in the United States and Canada, with international expansion underway including a Phase 3 trial of trofinetide for Rett syndrome in Japan; founded in 1993 as Receptor Technologies in Vermont and relocated to San Diego, California, in 1997, the company maintains headquarters at 12830 El Camino Real, Suite 400, San Diego, CA 92130. Recent developments include the initiation of a Phase 2 study for ACP-204 in Lewy body dementia psychosis and the Phase 3 Japan trial for trofinetide in 2025; appointment of Catherine Owen Adams as Chairperson of the Biotechnology Innovation Organization's Emerging Companies section and Executive Committee member; addition of Konstantina Katcheves as Senior Vice President and Chief Business and Strategy Officer to drive global partnerships and pipeline growth; extension of NUPLAZID patent protection to 2038; and an agreement in late 2024 to sell its rare pediatric disease priority review voucher for $150 million to fund commercial operations, R&D, and business development.
Company News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
Needham & Company LLC Reaffirms Buy Rating for ACADIA Pharmaceuticals (NASDAQ:ACAD)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
Can Nuplazid and Daybue Strengthen Acadia's Growth Prospects?
Reviewing ACADIA Pharmaceuticals (NASDAQ:ACAD) and C4 Therapeutics (NASDAQ:CCCC)
4 CNS Drug Stocks Worth Watching This World Mental Health Day
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
Acadia's Daybue Patent Allowance Extends U.S. Protection to March 2041
Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041
3 Stocks Put Traders Are Targeting Today: AMTX, ACAD, REZI
ACAD Stock Down 13% as Phase II Alzheimer's Study Misses Primary Goal
ACADIA Pharmaceuticals Inc. (ACAD) Discusses Top-Line Phase II Results From RADIANT Study of Remlifanserin in Alzheimer's Disease Psychosis Transcript
Acadia Drug Misses Primary Goal in Alzheimer's Related Psychosis
Acadia Pharmaceuticals: Remlifanserin Is In Trouble
Acadia Pharmaceuticals shares slide on mixed Alzheimer's psychosis data
ACADIA Advances 60 mg Remlifanserin After Near-Miss in Alzheimer's Psychosis Trial